...
首页> 外文期刊>Hormone and Metabolic Research >Stimulation of fat oxidation, but no sustained reduction of hepatic lipids by prolonged pharmacological inhibition of acetyl CoA carboxylase.
【24h】

Stimulation of fat oxidation, but no sustained reduction of hepatic lipids by prolonged pharmacological inhibition of acetyl CoA carboxylase.

机译:通过延长药理学抑制乙酰辅酶A羧化酶的作用来刺激脂肪氧化,但不能持续降低肝脂质。

获取原文
获取原文并翻译 | 示例
           

摘要

Acetyl CoA carboxylase isoforms 1 and 2 (ACC1/2) are key enzymes of fat metabolism and their inhibition has been postulated to be beneficial for the treatment of the metabolic syndrome by decreasing ectopic fat accumulation. In order to validate this approach pharmacologically, we characterized the chronic effect of the small molecule ACC1/2 inhibitor SAR210 in 2 rodent models of fatty liver. Chronic administration of SAR210 increased serum ketone levels in both diet-induced obese mice and female ZDF rats. The inhibitor neither reduced hepatic triglycerides nor influenced body weight in either diet-induced obese mice or female ZDF rats. Thus, chronic pharmacological inhibition of ACC1/2 stimulated fat oxidation, which was, however, not sufficient to reduce hepatic triglycerides.
机译:乙酰辅酶A羧化酶同工型1和2(ACC1 / 2)是脂肪代谢的关键酶,据推测它们的抑制作用通过减少异位脂肪的积累对治疗代谢综合症是有益的。为了在药理上验证该方法,我们在2种脂肪肝啮齿动物模型中表征了小分子ACC1 / 2抑制剂SAR210的慢性作用。长期施用SAR210可以增加饮食诱导的肥胖小鼠和雌性ZDF大鼠的血清酮水平。在饮食诱导的肥胖小鼠或雌性ZDF大鼠中,该抑制剂既不降低肝甘油三酸酯,也不影响体重。因此,ACC1 / 2的慢性药理抑制作用刺激了脂肪氧化,但是,这不足以减少肝甘油三酯。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号